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Amyloidogenesis, the progressive accu-
mulation of amyloid-beta (Aβ) peptides
into insoluble, toxic, senile plaque lesions
is one of the major defining features
of the Alzheimer’s disease (AD) brain.
Normally, Aβ42 peptides are cleared
from the extracellular space by natural
phagocytic mechanisms, but when this
intrinsic sensing and clearance system
is functionally compromised or defec-
tive, Aβ42 peptides accumulate. Largely
due to their intensely hydrophobic char-
acter, under physiological conditions
Aβ42 peptides have a strong tendency
to self-aggregate into higher order neu-
rotoxic and pro-inflammatory fibrillar
aggregates. While the Aβ peptide-clearing
mechanisms are highly complex, one par-
ticularly important molecular sensor for
Aβ42 peptide clearance is the triggering
receptor expressed in myeloid/microglial
cells 2 (TREM2; encoded at chr6p21.1),
a variably glycosylated 230 amino acid
transmembrane spanning stimulatory
receptor of the immunoglobulin/lectin-
like gene superfamily strongly associated
with innate-immune, pro-inflammatory,
and neurodegenerative signaling in AD.
TREM2 is highly and almost exclusively
expressed on the outer plasma mem-
brane of microglial cells, the resident
phagocytic and scavenging neuroimmune
macrophages of the human central ner-
vous system (CNS). As AD progresses,
microglia appear to become progres-
sively dysfunctional; TREM2 becomes
down-regulated and microglia lose their
ability to clear Aβ42 peptides while
producing and releasing neurotoxins,
reactive oxygen species (ROS), and pro-
inflammatory cytokines that further
promote Aβ42 production and patho-
logical aggregation (Schmid et al., 2002;
Alexandrov et al., 2013; Boutajangout
and Wisniewski, 2013; Hickman and El
Khoury, 2013).
Recently, much interest in the molec-
ular biology, genetics, and epigenetics of
TREM2 expression, and its potential for
sensing and scavenging Aβ42 peptides in
AD and other progressive neurodegener-
ative diseases has arisen. TREM2’s critical
importance is underscored by seven recent
observations: (1) that relatively rare muta-
tions of TREM2 (or of its coupling protein,
DAP12, also known as TYROBP; see
Figure 1) are currently associated with
the progressive, pre-senile dementing
illnesses Nasu-Hakola syndrome, polycys-
tic lipomembranous osteodysplasia with
sclerosing leucoencephalopathy (POSL),
sporadic amyotrophic lateral sclerosis
(ALS), and AD (Nimmerjahn et al.,
2005; Neumann and Takahashi, 2007;
Guerreiro and Hardy, 2013; Zhao and
Lukiw, 2013; Zhao et al., 2013; Cady
et al., 2014); (2) that down-regulation
in the phagocytic ability of microglia
to degrade Aβ42 peptides in AD, and
down-regulation in TREM2 expression,
has been reported in sporadic AD brain
tissues (Hickman and El Khoury, 2013;
Zhao et al., 2013); (3) that TREM2 knock-
down has been shown to exacerbate
age-related neuro-inflammation and
enhance cognitive deficiency in senescence
accelerated mouse prone 8 (SAMP8) mice
(Jiang et al., 2014); (4) that microglial
TREM2 gene expression in cell culture,
both at the level of mRNA and protein,
have been shown to be remarkably sen-
sitive to external cytokine stressors such
as tumor necrosis factor alpha (TNFα; a
pro-inflammatory adipokine known to
be up-regulated in AD brain; Zhao et al.,
2013; unpublished observations); (5) that
AD-relevant pro-inflammatory neurotox-
ins such as bacterial lipopolysaccharide
(LPS) and environmentally abundant
toxic metals such as aluminum strongly
down-regulate TREM2 and the ability of
microglial cells to phagocytose extracel-
lular debris (Hickman and El Khoury,
2013; Zhao et al., 2013; unpublished
observations); (6) that down-regulation
in the expression of TREM2 appears
to be regulated in part by the up-
regulation of the microglial-enriched,
NF-kB-sensitive microRNA-34a (miRNA-
34a), and perhaps other NF-kB-sensitive
miRNAs, and (7) that both anti-NF-kB
and anti-microRNA (AM-RNA) strate-
gies have been shown to be useful in
the restoration of homeostatic TREM2
gene expression levels and the neutral-
ization of pro-inflammatory signaling
and amyloidogenesis, at least in vitro
(Hill et al., 2009; Pogue et al., 2009,
2010; Alexandrov et al., 2012, 2013;
Zhao et al., 2013; unpublished obser-
vations). From what we know so far it
is tempting to speculate that (1) loss-
of function of TREM2 due to genetic
mutations in familial AD may have the
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FIGURE 1 | The triggering receptor expressed in myeloid/microglial cells type 2 (TREM2) is a
230 amino acid, ∼25.4 kDa integral trans-membrane glycoprotein sensor spanning the lipid
bilayer of CNS microglial cells. Very recently, TREM2 has been shown to act as a phagocytic
receptor of bacterial lipopolysaccharide (LPS), Aβ42 peptides and other cellular end-stage noxious
cellular products (N’Diaye et al., 2009; Guerreiro and Hardy, 2013; Jonsson et al., 2013). TREM2-LPS
or TREM2-Aβ peptide recognition may be achieved in part through a pathogen-associated molecular
pattern (PAMP) characteristic of highly specific molecular features located on LPS or Aβ42
molecules (Boutajangout and Wisniewski, 2013; Zhao et al., 2013; unpublished observations).
Transmembrane signaling via TREM2 is in part accomplished through a trans-membrane adapter,
tyrosine kinase binding protein called TYROBP, also known as the DNAX-activation protein 12
(DAP12) or the polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy
(PLOSL) protein (Schmid et al., 2002; Jonsson et al., 2013). TREM2 signaling triggers the
phagocytic uptake of cellular debris and is associated with the further down-stream induction of
reactive oxygen species (ROS) and the pro-inflammatory transcription factor NF-kB (Charles et al.,
2008; N’Diaye et al., 2009). Up-regulation of ROS and NF-kB are a characteristic feature of
inflammatory neurodegeneration and increasing Aβ42 peptide load in AD brain (Hickman and El
Khoury, 2013; Jonsson et al., 2013; Zhao et al., 2013). Interestingly, TREM2 expression is critical for
the clearance of neural debris of the injured or lesioned CNS, and loss-of-function mutations in
TREM2 or TYROBP (DAP12) are linked to presenile dementias characteristic of ALS or AD-type
neocortical degeneration (Charles et al., 2008; Guerreiro and Hardy, 2013; Cady et al., 2014; Jiang
et al., 2014). This highly schematicized figure was adapted in part from Nimmerjahn et al. (2005),
Neumann and Takahashi (2007), Guerreiro and Hardy (2013), and Neumann and Daly (2013).
same end effects on phagocytosis as down-
regulation of a fully functional TREM2
in sporadic AD; and that (2) modest
TREM2 over-expression might be useful
in enhancing the scavenging and removal
of cellular debris in the CNS, includ-
ing neurotoxic and self-aggregating Aβ42
peptides. Importantly, TREM2 signaling
has been recently shown to be selec-
tively inducible and manipulated from
outside of the cell, suggesting that the
modulation of TREM2 expression may
be effectively regulated using highly spe-
cific targeting via drug-based pharma-
cological strategies exogenously supplied
(Alexandrov et al., 2013; Lukiw, 2013;
Zhao et al., 2013).
AD represents a highly complex,
insidious, progressive, multi-factorial
brain dysfunction whose incidence is
reaching epidemic proportions. Despite
the billions of dollars already spent on AD
research, including multiple Aβ immu-
nization and immunotherapy strategies,
there is still no adequate treatment or
cure for AD, and the development and
implementation of novel, more effec-
tive treatment strategies are critical.
Recruitment and harvesting of the TREM2
mechanism as a potent, endogenous Aβ42-
peptide scavenging activity may represent
a singularly attractive new direction for
the clinical management of AD. Indeed, as
a natural sensor and scavenger of noxious
cellular debris TREM-2 stimulation may
turn out (1) to be remarkably neuropro-
tective against both amyloidogenesis and
age-related neuro-inflammation; while
(2) significantly reducing the progres-
sive cognitive impairment associated with
amyloidogenesis and inflammatory neu-
rodegeneration in the CNS (Hickman and
El Khoury, 2013; Zhao et al., 2013; Cady
et al., 2014; Jiang et al., 2014). Put another
way, a decline in TREM2’s contribution
to the innate immune response, in part
driving amyloid-clearance deficits and
progressive degeneration characteristic
of the AD process, suggest novel ther-
apeutic targets and treatment strategies
directed at maintaining natural and home-
ostatic TREM2 functions. This may be
accomplished not only through the direct
stimulation of TREM2 itself but also
through the poorly understood down-
stream TREM2-linked TYROBP (DAP12)
signaling pathways responsible for; (1)
the actual phagocytosis of extracellular
molecules; (2) the production of damag-
ing quantities of ROS; (3) the induction
of pro-inflammatory signals via NF-kB;
and (4) the maintenance of homeo-
static microglial function that together
may diminish amyloidogenesis and the
intercellular propagation of pathogenic
signaling in the AD affected brain
(Boutajangout and Wisniewski, 2013;
Guerreiro and Hardy, 2013; Zhao and
Lukiw, 2013; Jiang et al., 2014; Figure 1).
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